<DOC>
	<DOCNO>NCT00671970</DOCNO>
	<brief_summary>Primary objective : To estimate 6-month progression free survival probability pt w recurrent malignant glioma treat w erlotinib + bevacizumab . Secondary Objectives : To evaluate safety &amp; tolerability erlotinib + bevacizumab among pt w recurrent malignant glioma To evaluate radiographic response pt w recurrent malignant glioma treat w erlotinib + bevacizumab To evaluate pharmacokinetics erlotinib administer pt w recurrent malignant glioma ; &amp; examine relationship clinical response Epidermal Growth Factor ( EGFR ) expression , amplification , &amp; v-III mutation , phosphatase tensin homolog ( PTEN ) expression , vascular endothelial growth factor ( VEGF ) expression , vascular endothelial growth factor receptor 2 ( VEGFR-2 ) &amp; phosphorylated protein kinase B ( PKB/Akt ) archival tumor sample</brief_summary>
	<brief_title>Phase ( Ph ) II Bevacizumab + Erlotinib Patients ( Pts ) With Recurrent Malignant Glioma ( MG )</brief_title>
	<detailed_description>Exploratory , Phase II study design assess anti-tumor activity combinatorial regimen consist erlotinib + bevacizumab among pt w recurrent malignant glioma . Signal transduction inhibitor , erlotinib , well anti-angiogenic agent , bevacizumab , expect exert cytostatic anti-tumor effect . Primary endpoint study probability progression-free survival 6 month . An important secondary objective ass safety erlotinib + bevacizumab pt w RMG . Pharmacokinetic study include protocol evaluate impact enzyme-inducing anti-epileptic drug ( EIAEDs ) metabolism erlotinib . If study demonstrate combo regimen erlotinib + bevacizumab associate w encouraging anti-tumor activity among pt w recurrent malignant glioma ( RMG ) , assessment regimen additional ph II &amp; possibly ph III study , consider .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Pts histologically confirm diagnosis recurrent/progressive WHO gr III &amp; IV MG &amp; meet following inclusion criterion : Age &gt; 18 yr Interval &gt; 4 wks since prior surgery Interval &gt; 4 wks since prior external beam radiation therapy ( XRT ) chemo , unless unequivocal evidence progressive disease &amp; pt recover anticipated toxicity recent therapy Karnofsky performance status score &gt; 60 Hematocrit &gt; 29 percent , absolute neutrophil count ( ANC ) &gt; 1,500 cells/microliter , platelet &gt; 100,000 cells/microliter Serum creatinine &lt; .5mg/dl , blood urea nitrogen ( BUN ) &lt; 25 mg/dl , serum glutamate oxaloacetate transaminase ( SGOT ) &amp; bilirubin &lt; 1.5 x upper limit normal ( ULN ) For pt corticosteroid , stable dose 1 wk prior entry Pts prior bevacizumab eligible however interval &gt; 6 wks must elapse since last dose Signed informed consent approve Institutional Review Board ( IRB ) prior patient entry ; If sexually active , pt must agree take contraceptive measure duration treatment Prior therapy w either bevacizumab/EGFRdirected agent &gt; 3 prior recurrence Pregnancy/breast feed Comedication w immunosuppressive agent corticosteroid include limited cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil Evidence central nervous system ( CNS ) hemorrhage baseline MRI CT scan Pts require therapeutic anticoagulation Uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic &amp; psychiatric illness/social situation would limit compliance w study requirement , disorder associate w significant immunocompromised state Pts w another primary malignancy require treatment within past year Pts w acute/chronic renal insufficiency/those w acute renal insufficiency severity due hepatorenal syndrome/in perioperative liver transplantation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Recurrent MG</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Glioma</keyword>
	<keyword>Glioblastoma multiforme ( GBM )</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Anaplastic oligodendroglioma</keyword>
	<keyword>Anaplastic oligoastrocytoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
</DOC>